Keyphrases
Atorvastatin
98%
Diabetes
96%
Type 2 Diabetes Mellitus (T2DM)
96%
Type 2 Diabetic Patients
44%
Cardiovascular Disease
42%
Type 1 Diabetes Mellitus (T1DM)
39%
Patients with Diabetes
31%
Type I Diabetes
28%
Scotland
28%
Population Cohort Study
25%
Cardiovascular Risk Prediction
25%
Comorbidity
24%
Competing Risks
23%
Risk Prediction Tool
22%
Scottish
22%
Cardiovascular Risk
22%
Hip Fracture
21%
Older People
21%
External Validation
20%
Performance Prediction
20%
COVID-19
18%
Statin Therapy
18%
QRISK3
17%
Socioeconomic Status
16%
Incident Cardiovascular Disease
15%
Statins
15%
Competing Mortality Risk
15%
C-reactive Protein
15%
LDL Cholesterol
15%
Confidence Interval
14%
Cardiovascular Prevention
14%
QFracture
13%
Prediction Tool
13%
Randomized Controlled Trial
13%
Placebo
12%
Lipoproteins
12%
Linkage Study
12%
Hemoglobin A1c (HbA1c)
11%
Metformin
11%
Osteoporotic Fractures
9%
Hazard Ratio
9%
Randomized Placebo-controlled Trial
9%
Relative Risk
9%
Validation Cohort
9%
Life Expectancy
9%
Apolipoprotein B (Apo B)
9%
Cumulative Exposure
8%
Area under the Receiver Operating Characteristic Curve
8%
Risk Model
8%
Apolipoprotein C-III
8%
Pharmacology, Toxicology and Pharmaceutical Science
Non Insulin Dependent Diabetes Mellitus
100%
Atorvastatin
86%
Cardiovascular Disease
55%
Insulin Dependent Diabetes Mellitus
32%
Statin (Protein)
28%
Hip Fracture
25%
Disease
25%
Placebo
21%
Coronavirinae
18%
Fragility Fracture
18%
Cardiovascular Risk
15%
Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor
14%
Comorbidity
14%
Ischemic Heart Disease
13%
Randomized Controlled Trial
13%
Cohort Study
13%
Low Density Lipoprotein Cholesterol
12%
Life Expectancy
12%
Observational Study
12%
High Density Lipoprotein Cholesterol
12%
Biological Marker
12%
Cerebrovascular Accident
11%
Diabetes Mellitus
11%
Apolipoprotein B
10%
C Reactive Protein
10%
Anti-Inflammatory Drug
8%
Prevalence
7%
Vascular Disease
7%
Cross-Sectional Study
7%
Metformin
6%
Brain Natriuretic Peptide
6%
Quercetin
6%
Rosiglitazone
6%
Curcumin
6%
Apolipoprotein C3
6%
Cholecalciferol
6%
Controlled Clinical Trial
6%
Cell Adhesion Molecule 1
6%
Replacement Therapy
6%
Severe Dengue
6%
End Stage Renal Disease
6%
Tumor Necrosis
6%
Pioglitazone
6%
Case Fatality Rate
6%
Vascular Cell Adhesion Molecule 1
6%
Colchicine
6%
Lipoprotein A
6%
Advanced Glycation End Product Receptor
6%
Retrospective Study
6%
Congestive Heart Failure
6%
Medicine and Dentistry
Maturity Onset Diabetes of the Young
52%
Diabetes
40%
Cardiovascular Disease
27%
Cohort Analysis
26%
Cardiovascular Risk
25%
Insulin Dependent Diabetes Mellitus
20%
Atorvastatin
20%
Hip Fracture
18%
Comorbidity
17%
Socioeconomic Status
16%
Randomized Controlled Trial
12%
Life Expectancy
12%
COVID-19
12%
Fragility Fracture
12%
Statin
11%
Primary Health Care
9%
Prevalence
8%
Diabetes Mellitus
8%
Vascular Disease
7%
Primary Prevention
7%
Placebo
7%
Gene Linkage
7%
Cohort Effect
6%
Arm
6%
Supplementation
6%
Gel Electrophoresis
6%
Meta-Analysis
6%
Apolipoprotein C3
6%
Cardiovascular System
6%
Lifespan
6%
Ataxia Telangiectasia
6%
Glycemic Control
6%
Adjuvant Therapy
6%
Treatment Response
6%
Observational Study
6%
Case Fatality Rate
6%
Quercetin
6%
Apolipoprotein B
6%
Apolipoprotein
6%
Glycon
6%
Colecalciferol
6%
Curcumin
6%
Retrospective Study
6%
High Density Lipoprotein Cholesterol
6%
Hormone Precursor
6%
Amino Terminal Sequence
6%
Brain Natriuretic Peptide
6%
Tocilizumab
6%
NMR Spectroscopy
6%
Renal Replacement Therapy
6%
